123 related articles for article (PubMed ID: 24490776)
1. Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification.
Welinder C; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Breslin T; Rezeli M; Jansson B; Laurell T; Fehniger TE; Wieslander E; Pawlowski K; Marko-Varga G
J Proteome Res; 2014 Mar; 13(3):1315-26. PubMed ID: 24490776
[TBL] [Abstract][Full Text] [Related]
2. TRIB2 as a biomarker for diagnosis and progression of melanoma.
Hill R; Kalathur RK; Colaço L; Brandão R; Ugurel S; Futschik M; Link W
Carcinogenesis; 2015 Apr; 36(4):469-77. PubMed ID: 25586991
[TBL] [Abstract][Full Text] [Related]
3. Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay.
Blokzijl A; Chen LE; Gustafsdottir SM; Vuu J; Ullenhag G; Kämpe O; Landegren U; Kamali-Moghaddam M; Hedstrand H
PLoS One; 2016; 11(4):e0154214. PubMed ID: 27110718
[TBL] [Abstract][Full Text] [Related]
4. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma.
Yang L; Chen Y; Cui T; Knösel T; Zhang Q; Geier C; Katenkamp D; Petersen I
Hum Pathol; 2012 Sep; 43(9):1463-70. PubMed ID: 22406360
[TBL] [Abstract][Full Text] [Related]
5. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
[TBL] [Abstract][Full Text] [Related]
6. High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma.
Falkenius J; Lundeberg J; Johansson H; Tuominen R; Frostvik-Stolt M; Hansson J; Egyhazi Brage S
Melanoma Res; 2013 Dec; 23(6):452-60. PubMed ID: 24128789
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
8. S100, HMB-45, and Melan-A negative primary melanoma.
Shinohara MM; Deubner H; Argenyi ZB
Dermatol Online J; 2009 Sep; 15(9):7. PubMed ID: 19930994
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
10. Gene expression patterns in melanocytic cells: candidate markers for early stage and malignant transformation.
Meije CB; Hakvoort TB; Swart GW; Westerhof W; Lamers WH; Das PK
J Pathol; 2002 Jan; 196(1):51-8. PubMed ID: 11748642
[TBL] [Abstract][Full Text] [Related]
11. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-associated antigens as messenger RNA detection markers for melanoma.
Sarantou T; Chi DD; Garrison DA; Conrad AJ; Schmid P; Morton DL; Hoon DS
Cancer Res; 1997 Apr; 57(7):1371-6. PubMed ID: 9102226
[TBL] [Abstract][Full Text] [Related]
13. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
14. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
15. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
16. Systematic search for the best gene expression markers for melanoma micrometastasis detection.
Soikkeli J; Lukk M; Nummela P; Virolainen S; Jahkola T; Katainen R; Harju L; Ukkonen E; Saksela O; Hölttä E
J Pathol; 2007 Oct; 213(2):180-9. PubMed ID: 17891747
[TBL] [Abstract][Full Text] [Related]
17. A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma.
Sykes EK; McDonald CE; Ghazanfar S; Mactier S; Thompson JF; Scolyer RA; Yang JY; Mann GJ; Christopherson RI
Proteomics Clin Appl; 2018 May; 12(3):e1700094. PubMed ID: 29227041
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical diagnostic and prognostic markers for melanoma.
Nosrati M; Kashani-Sabet M
Methods Mol Biol; 2014; 1102():259-73. PubMed ID: 24258983
[TBL] [Abstract][Full Text] [Related]
19. Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assay.
Welinder C; Jönsson GB; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Breslin T; Rezeli M; Jansson B; Fehniger TE; Laurell T; Wieslander E; Pawlowski K; Marko-Varga G
PLoS One; 2014; 9(10):e110804. PubMed ID: 25333933
[TBL] [Abstract][Full Text] [Related]
20. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
